Clinical Trials Logo

Clinical Trial Summary

To identify the frequency of ATM and its different aetiologies, alongside the different clinical and radiological patterns and prognostic factors .


Clinical Trial Description

Acute transverse myelitis (ATM) is an inflammatory condition of the spinal cord, covering the entire cross section and spreading on two or more vertebral segments, without evidence of a compressive lesion.1 This shows clinically as acute or subacute spinal cord dysfunction resulting in paresis, sensory level, and autonomic (bladder, bowel, and sexual) impairment below the level of the lesion.2 ATM is typically classified as either idiopathic ATM where no causative factor found or disease- associated transverse myelitis.3 Disease- associated transverse myelitis results from heterogenous pathophysiologic causes including infectious, parainfectious, paraneoplastic, drug/toxin-induced, systemic autoimmune disorders (SAIDs), Neurosarcoidosis and acquired demyelinating diseases like multiple sclerosis (MS) or neuromyelitis optica (NMO).4 5 6 The annual incidence of ATM ranges from 1.34 to 4.60 cases per million,7 8 but increases to 24.6 cases per million if acquired demyelinating diseases like MS are included.9 TM can occur at any age, although a bimodal peak in incidence occurs in the second and fourth decades of life.7 8 10 This broad differential can overlap with noninflammatory myelopathies and can be very challenging for clinicians to navigate, causing delays in diagnosis or treatment.11 MRI is essential to rule out compressive causes of these neurologic manifestations, such as tumour, epidural abscess, herniated disc, stenosis of the medullary canal or hematoma. It is also used to show the extension of the lesion and for follow-up progress of these lesions after treatment.12 The lack of large-scale and longitudinal studies has hindered the understanding of this complex disorder. Approximately 33% of patients recover with little to no lasting deficits, 33% have a moderate degree of permanent disability, and 33% are permanently disabled.13 The disease is often a monophasic illness and will only not recur unless it is secondary to a chronic comorbid condition, highlight the need for early and prompt recognition of aetiology. Steroids and immunosuppression are the only potential treatments for ATM at this time, but there is potential for monoclonal antibody drugs that might alter the disease course if an autoinflammatory process was identified. Although individuals affected by ATM show residual neurologic deficits if they have not recovered to normal within 3-6 months, no report has considered earlier factors that might determine the prognosis of the illness. The objective of this study was to determine frequency of ATM and its different etiologies, clinical and radiological patterns, and the different prognostic factors associated in a large tertiary center in the south of Egypt with a goal to improve awareness of ATM to ensure prompt recognition and treatment ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06055998
Study type Observational
Source Assiut University
Contact Fouad E Fawaz, Resident
Phone +201030698686
Email fouadabdelrahman55@gmail.com
Status Not yet recruiting
Phase
Start date December 2023
Completion date February 2026

See also
  Status Clinical Trial Phase
Recruiting NCT03887273 - Study to Investigate the Safety of the Transplantation of Human Glial Restricted Progenitor Cells Into Subjects With Transverse Myelitis Phase 1/Phase 2
Recruiting NCT04721717 - AIM's Writing for Healing: A Workshop for Individuals Living With Paralysis
Recruiting NCT05630313 - Gene Sequencing as a Strategy for Identifying Genetic Factors Associated With Serious Adverse Events After Covid-19 Vaccines in Use in Brazil
Completed NCT03942952 - PEDIATRIC SONICS: Pediatric Study of Neuropsychology and Imaging in CNS Demyelinating Syndromes.
Recruiting NCT06147258 - The Impact of Expressive Emotional Writing on Facilitating Grief Resolution in Adults With Spinal Cord Injury N/A
Active, not recruiting NCT00445367 - Biobank For MS And Other Demyelinating Diseases
Recruiting NCT01623076 - The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders
Terminated NCT01446575 - Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis Phase 4
Active, not recruiting NCT04564495 - Home Based Tele-exercise for People With Chronic Neurological Impairments N/A
Enrolling by invitation NCT00704626 - Serum Auto-Antibodies in Neurological Diseases
Completed NCT02341950 - Clinical Trial of a Serious Game for Individuals With SCI/D N/A
Completed NCT02166346 - Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch) Phase 2
Completed NCT00179478 - Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis Phase 4
Completed NCT03336762 - Injured Spinal Cord Pressure Evaluation Study - Transverse Myelitis
Recruiting NCT05249595 - Ultrasound Imaging Based Sensing of Human Ankle Motion Intent and Control Strategies for Ankle Assistance N/A
Enrolling by invitation NCT06163508 - A Long Term Follow-Up Study for Subjects Who Have Received Q-Cells
Completed NCT03138421 - Central Pain Study for ABX-1431 Phase 1
Recruiting NCT05017142 - Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)